Der rheumatologische Patient auf der Intensivstation

Moreels Ml, Mélot C, Leeman M (2005) Prognosis of patients with systemic rheumatic diseases admitted to the intensive care unit. Intensive Care Med 31(4):591–593 Dong Mj, Zhao K, Liu ZF et al (2011) A meta-analysis of the value of fluorodeoxyglucose-PET/PET-CT in the evaluation of fever of unknown origin. Eur J Radiol 80(3):834–844 (In Press, Corrected Proof) Schmidt J, Duhaut P, Bourgeois AM et al (2009) Procalcitonin at the onset of giant cell arteritis and polymyalgia rheumatica: the GRACG prospective study. Rheumatology 48:158–159 Sleglova O, Dejmkova H, Uhrova J, Belacek J (2010) Usefulness of procalcitonin measurement in differentiating between activity of systemic autoimmune disease and bacterial infection. Arthritis Rheum 62(Suppl):687 Limper M, Kruif MD de, Duits AJ et al (2010) The diagnostic role of Procalcitonin and other biomarkers in discriminating infectious from non-infectious fever. J Infect 60:409–416 Saravanan V, Kelly CA (2004) Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology 43(2):143–147 Chikura B, Lane S, Dawson JK (2009) Clinical expression of leflunomide-induced pneumonitis. Rheumatology 48:1065–1068 Lehmann P, Fleck M, Schoelmerich J, Haerle P (2010) Azathioprine-associated hypersensitivity reaction in a patient with Churg Strauss vasculitis. J Clin Rheumatol 16(5):242–243 Kramer L (1998) Indikation und Komplikation der Plasmapherese im Rahmen der Intensivmedizin. Intensivmed 35(5):349–355 Lionaki S, Falk RJ (2007) Removing antibody and preserving glomeruli in ANCA small-vessel vasculitis. J Am Soc Nephrol 18:1987–1989 Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus Cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232 Zhu LJ, Yang X, Yu XQ (2010) Anti-TNF-α therapies in systemic lupus erythematosus. J Biomed Biotechnol Jong MFC de, Beishuizen A, Schijndel RJMS van et al (2011) Risk factors and outcome of changes in adrenal response to ACTH in the course of critical illness. J Intensive Care Med Haerle P Straub R, Fleck M (2010) Perioperative management of immunosuppression in rheumatic diseases – what to do. Rheumatol Int 30(8):999–1004 Marik PE (2009) Critical illness-related corticosteroid insufficiency. Chest 135:181–193 Schneeweiss S, Setoguchi S, Weinblatt ME et al (2007) Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 56(6):1754–1764 Listing J, Strangfeld A, Kary S et al (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52:3403–3412 Dixon WG, Watson K, Lunt M et al (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54(8):2368–2376 Bongartz T, Sutton AJ, Sweeting MJ et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 295(19):2275–2285 Fachinformation Leflunomid, Stand 07/2010. 2010 Charpin C, Guis S, Colson P et al (2009) Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 11:R179 Cavallasca JA, Rosario Maliandi Ma del, Sarquis S et al (2010) Outcome of patients with systemic rheumatic diseases admitted to a medical intensive care unit. J Clin Rheumatol 16 Feng PH, Lin SM, Yu CT et al (2010) Inadequate antimicrobial treatment for nosocomial infection is a mortality risk factor for systemic lupus erythematosus patients admitted to intensive care unit. Am J Med Sci 340(1):64–68  Ñamendys-Silva SA, Baltazar-Torres JA et al (2009) Prognostic factors in patients with systemic lupus erythematosus admitted to the intensive care unit. Lupus 18:1252–1258 Sherer Y, Shepshelovich D, Shalev T et al (2007) Outcome of patients having dermatomyositis admitted to the intensive care unit. Clin Rheumatol 26(11):1851–1855 Shalev T, Haviv Y, Segal E et al (2006) Outcome of patients with scleroderma admitted to intensive care unit. A report of nine cases. Clin Exp Rheumatol 24:380–386 Camargo JF, Tobó n GJ, Fonseca N et al (2005) Autoimmune rheumatic diseases in the intensive care unit: experience from a tertiary referral hospital and review of the literature. Lupus 14(4):315–320 Hsu CL, Chen KY, Yeh PS et al (2005) Outcome and prognostic factors in critically ill patients with systemic lupus erythematosus: a retrospective study. Crit Care 9:R177–R183 Whitelaw DA, Gopal R, Freeman V (2005) Survival of patients with SLE admitted to an intensive care unit – a retrospective study. Clin Rheumatol 24(3):223–227 Alzeer AH, Al-Arfaj A, Basha SJ et al (2004) Outcome of patients with systemic lupus erythematosus in intensive care unit. Lupus 13(7):537–542 Williams FMK, Chinn S, Hughes GRV, Leach RM (2002) Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome. Ann Rheum Dis 61(5):414–421 Thong BY, Tai DY, Goh SK, Johan A (2001) An audit of patients with rheumatic disease requiring medical intensive care. Ann Acad Med Singapore 30:254–259